FindTrial
Sign In

A study to evaluate the spread and control of fungal infections in seriously ill patients

Epidemiology of Invasive fungal infections in critically ill cancer patients and ICU outcomes (IFI study) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/087917
Enrollment
100
Registered
2025-05-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms Health Condition 2: B99-B99- Other infectious diseases

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Tata Memorial Hospital,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All critically ill adult patients above 18 years admitted to ICU Started or ongoing Anti-fungal therapy by clinician. Both hematological and solid organ malignancies. Both medical and surgical patients admitted to TMH Mumbai MICU and SICU

Exclusion criteria

Exclusion criteria: Patients with Superficial or mucosal fungal infections Patients with Non invasive allergic fungal disease Patients with Antifungal prophylaxis

Design outcomes

Primary

MeasureTime frame
ICU mortality in patients with invasive fungal infections in adult oncology settingTimepoint: At ICU discharge—

Secondary

MeasureTime frame
90 day mortality Clinical response Days on mechanical ventilation Days on vasopressors Need for RRT (Renal replacement therapy)Timepoint: At 90 days from ICU admission—

Countries

India

Contacts

Public ContactDr Sudivya Sharma

Tata Memorial Hospital

drsudivyasharma@gmail.com9892762615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026